Communiqués TempraMed Technologies Ltd.

Actions

VIVI

CA88024B1022

Equipement, fournitures et distribution médicale

Marché Fermé - Canadian Securities Exchange 21:58:15 06/10/2026			Varia. 5j.	Varia. 1 janv.
0,5200 ^CAD	0,00%		+8,33%	-51,85%

01/10	TempraMed Technologies lève 1,2 million de dollars via un placement privé sans intermédiaire	MT
29/09	TempraMed Technologies Ltd. signe une lettre d’intention avec Cyprus Pharmaceutical Organization Ltd. pour la distribution exclusive des produits VIVI à Chypre	CI

Communiqués

05/10	TempraMed Announces VIVI Cap Smart Connectivity with Apple Health and Google Fit, Providing Better Health Outcomes and Data Tracking	NE
01/10	TempraMed Technologies Ltd. Announces Closing of Private Placement	NE
29/09	TempraMed Signs Letter of Intent with CPO Cyprus for Exclusive Distribution of VIVI Products in Cyprus	NE
28/09	TempraMed Announces Upsize to Offering	NE
24/09	TempraMed Expands Latin American Distribution Agreement with TEM and Receives Additional Commercial Order, Announces Private Placement	NE
23/09	TempraMed Announces Distribution Agreement with CenterWell Pharmacy(R), the Pharmacy Services Brand of Humana	NE
18/09	TempraMed Reports Record July Sales and Strong August Performance, with Year-to-Date Sales Already Exceeding Full-Year 2025 Revenue	NE
01/09	TempraMed Signs Letter of Intent with CPO Greece for Exclusive Distribution of VIVI Products in Greece	NE
25/08	TempraMed Signs Definitive Five-Year Saudi Arabia Distribution Agreement for Private-Label VIVI Cap	NE
20/08	TempraMed Announces Extension of Maccabi Healthcare Services Agreement	NE
18/08	TempraMed Executes Definitive Exclusive Distribution Agreement with TEM in Panama, Advancing Commercial Expansion Across Clinics and Pharmacies	NE
04/08	TempraMed Announces Strategic Partnership with Stealth Health, a Leading Telemedicine Platform for Longevity and Wellness	NE
30/07	TempraMed Uplists to OTCQB Venture Market and Achieves DTC Eligibility, Expanding Access to U.S. Investors	NE
09/07	TempraMed Expands Institutional Healthcare Network with Meuhedet Health Services, a Leading HMO in Israel, Covering over 1 Million Lives	NE
06/07	TempraMed Signs LOI for Exclusive Distribution in Kuwait, Expanding Presence in High-Growth Gulf Region Healthcare Market	NE
30/06	TempraMed Expands Strategic Partnership with McKesson Medical-Surgical to Accelerate North American Growth and Launch Full Portfolio Across B2B Channels	NE
26/06	TempraMed Signs Non-Binding LOI with National Distributor in Saudi Arabia	NE
04/06	TempraMed Signs Agreement for Exclusive Distribution Partnership in Brazil, One of the Largest Diabetes and Biologics Markets Globally	NE
22/05	TempraMed Featured on Dr. Phil Show in National US Broadcast Highlighting the Risk of Temperature Exposure for Insulin and Other Medications	NE
14/05	TempraMed Announces Granted Indian Design Patent for VIVI Cap Smart Product	NE
29/04	TempraMed Announces Continuance into Ontario	NE
07/04	TempraMed Announces Additional Granted Brazilian Patent for Newest VIVI Box Product	NE
30/03	TempraMed Signs LOI for Distribution Agreement in Panama, Expanding Central American Exposure	NE
24/03	TempraMed Strengthens Global Intellectual Property Position with Granted Chinese Patent for Newest Product, VIVI Box	NE
11/03	TempraMed's Independently Validated Payer ROI Model for Reimbursement Further Reinforced by a Scientific Publication Highlighting Clinical and Economic Rationale for VIVI Cap	NE